Herantis Pharma

Herantis Pharma is a Finnish public biotech company targeting neurodegenerative disorders, primarily Parkinson's disease, with its lead asset HER-096. The company has successfully completed a Phase 1a trial in healthy volunteers and is currently conducting a Phase 1b trial in Parkinson's patients. Herantis leverages a platform based on the CDNF protein mechanism to develop convenient, subcutaneously administered therapies aimed at stopping or reversing disease progression.

Platform based on the cerebral dopamine neurotrophic factor (CDNF) protein. Develops small synthetic peptidomimetic molecules (e.g., HER-096) designed from the CDNF active site for subcutaneous administration and blood-brain barrier penetration.

Herantis competes in the crowded Parkinson's disease space against large pharma and biotech companies developing symptomatic treatments and novel disease-modifying approaches targeting alpha-synuclein, inflammation, and other neurotrophic factors. Its differentiation lies in the CDNF mechanism and convenient subcutaneous delivery.